A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
Identifieur interne : 001D22 ( PubMed/Corpus ); précédent : 001D21; suivant : 001D23A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
Auteurs : Carmen S M. Yong ; Liza B. John ; Christel Devaud ; Miles H. Prince ; Ricky W. Johnstone ; Joseph A. Trapani ; Phillip K. Darcy ; Michael H. KershawSource :
- Oncotarget [ 1949-2553 ] ; 2016.
Abstract
While adoptive immunotherapy using chimeric antigen receptor (CAR)-modified T cells can induce remission of some tumors, the role of other CAR-modified leukocytes is not well characterized. In this study, we characterize the function of leukocytes including natural killer (NK) cells, macrophages and CAR T cells from transgenic mice expressing a CAR under the control of the pan-hematopoietic promoter, vav, and determine the ability of these mice to respond to ERB expressing tumors. We demonstrate the anti-tumor functions of leukocytes, including antigen specific cytotoxicity and cytokine secretion. The adoptive transfer of CAR T cells provided a greater survival advantage in the E0771ERB tumor model than their wildtype (WT) counterparts. In addition, CAR NK cells and CAR T cells also mediated increased survival in the RMAERB tumor model. When challenged with Her2 expressing tumors, F38 mice were shown to mount an effective immune response, resulting in tumor rejection and long-term survival. This was shown to be predominantly dependent on both CD8+ T cells and NK cells. However, macrophages and CD4+ T cells were also shown to contribute to this response. Overall, this study highlights the use of the vav-CAR mouse model as a unique tool to determine the anti-tumor function of various immune subsets, either alone or when acting alongside CAR T cells in adoptive immunotherapy.
DOI: 10.18632/oncotarget.9149
PubMed: 27153556
Links to Exploration step
pubmed:27153556Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.</title><author><name sortKey="Yong, Carmen S M" sort="Yong, Carmen S M" uniqKey="Yong C" first="Carmen S M" last="Yong">Carmen S M. Yong</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="John, Liza B" sort="John, Liza B" uniqKey="John L" first="Liza B" last="John">Liza B. John</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Devaud, Christel" sort="Devaud, Christel" uniqKey="Devaud C" first="Christel" last="Devaud">Christel Devaud</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Prince, Miles H" sort="Prince, Miles H" uniqKey="Prince M" first="Miles H" last="Prince">Miles H. Prince</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Johnstone, Ricky W" sort="Johnstone, Ricky W" uniqKey="Johnstone R" first="Ricky W" last="Johnstone">Ricky W. Johnstone</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Trapani, Joseph A" sort="Trapani, Joseph A" uniqKey="Trapani J" first="Joseph A" last="Trapani">Joseph A. Trapani</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Darcy, Phillip K" sort="Darcy, Phillip K" uniqKey="Darcy P" first="Phillip K" last="Darcy">Phillip K. Darcy</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Kershaw, Michael H" sort="Kershaw, Michael H" uniqKey="Kershaw M" first="Michael H" last="Kershaw">Michael H. Kershaw</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27153556</idno><idno type="pmid">27153556</idno><idno type="doi">10.18632/oncotarget.9149</idno><idno type="wicri:Area/PubMed/Corpus">001D22</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D22</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.</title><author><name sortKey="Yong, Carmen S M" sort="Yong, Carmen S M" uniqKey="Yong C" first="Carmen S M" last="Yong">Carmen S M. Yong</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="John, Liza B" sort="John, Liza B" uniqKey="John L" first="Liza B" last="John">Liza B. John</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Devaud, Christel" sort="Devaud, Christel" uniqKey="Devaud C" first="Christel" last="Devaud">Christel Devaud</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Prince, Miles H" sort="Prince, Miles H" uniqKey="Prince M" first="Miles H" last="Prince">Miles H. Prince</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Johnstone, Ricky W" sort="Johnstone, Ricky W" uniqKey="Johnstone R" first="Ricky W" last="Johnstone">Ricky W. Johnstone</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Trapani, Joseph A" sort="Trapani, Joseph A" uniqKey="Trapani J" first="Joseph A" last="Trapani">Joseph A. Trapani</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Darcy, Phillip K" sort="Darcy, Phillip K" uniqKey="Darcy P" first="Phillip K" last="Darcy">Phillip K. Darcy</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Kershaw, Michael H" sort="Kershaw, Michael H" uniqKey="Kershaw M" first="Michael H" last="Kershaw">Michael H. Kershaw</name><affiliation><nlm:affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Oncotarget</title><idno type="eISSN">1949-2553</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">While adoptive immunotherapy using chimeric antigen receptor (CAR)-modified T cells can induce remission of some tumors, the role of other CAR-modified leukocytes is not well characterized. In this study, we characterize the function of leukocytes including natural killer (NK) cells, macrophages and CAR T cells from transgenic mice expressing a CAR under the control of the pan-hematopoietic promoter, vav, and determine the ability of these mice to respond to ERB expressing tumors. We demonstrate the anti-tumor functions of leukocytes, including antigen specific cytotoxicity and cytokine secretion. The adoptive transfer of CAR T cells provided a greater survival advantage in the E0771ERB tumor model than their wildtype (WT) counterparts. In addition, CAR NK cells and CAR T cells also mediated increased survival in the RMAERB tumor model. When challenged with Her2 expressing tumors, F38 mice were shown to mount an effective immune response, resulting in tumor rejection and long-term survival. This was shown to be predominantly dependent on both CD8+ T cells and NK cells. However, macrophages and CD4+ T cells were also shown to contribute to this response. Overall, this study highlights the use of the vav-CAR mouse model as a unique tool to determine the anti-tumor function of various immune subsets, either alone or when acting alongside CAR T cells in adoptive immunotherapy.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27153556</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>22</Day></DateCreated><DateRevised><Year>2017</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1949-2553</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>23</Issue><PubDate><Year>2016</Year><Month>Jun</Month><Day>07</Day></PubDate></JournalIssue><Title>Oncotarget</Title><ISOAbbreviation>Oncotarget</ISOAbbreviation></Journal><ArticleTitle>A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.</ArticleTitle><Pagination><MedlinePgn>34582-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.18632/oncotarget.9149</ELocationID><Abstract><AbstractText>While adoptive immunotherapy using chimeric antigen receptor (CAR)-modified T cells can induce remission of some tumors, the role of other CAR-modified leukocytes is not well characterized. In this study, we characterize the function of leukocytes including natural killer (NK) cells, macrophages and CAR T cells from transgenic mice expressing a CAR under the control of the pan-hematopoietic promoter, vav, and determine the ability of these mice to respond to ERB expressing tumors. We demonstrate the anti-tumor functions of leukocytes, including antigen specific cytotoxicity and cytokine secretion. The adoptive transfer of CAR T cells provided a greater survival advantage in the E0771ERB tumor model than their wildtype (WT) counterparts. In addition, CAR NK cells and CAR T cells also mediated increased survival in the RMAERB tumor model. When challenged with Her2 expressing tumors, F38 mice were shown to mount an effective immune response, resulting in tumor rejection and long-term survival. This was shown to be predominantly dependent on both CD8+ T cells and NK cells. However, macrophages and CD4+ T cells were also shown to contribute to this response. Overall, this study highlights the use of the vav-CAR mouse model as a unique tool to determine the anti-tumor function of various immune subsets, either alone or when acting alongside CAR T cells in adoptive immunotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yong</LastName><ForeName>Carmen S M</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Liza B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devaud</LastName><ForeName>Christel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Recherche en Santé Digestive, Université de Toulouse, INPT, INRA, INSERM UMR1220, UPS, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prince</LastName><ForeName>Miles H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnstone</LastName><ForeName>Ricky W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trapani</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darcy</LastName><ForeName>Phillip K</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Monash University, Prahran Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kershaw</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology, Monash University, Prahran Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Oncotarget</MedlineTA><NlmUniqueID>101532965</NlmUniqueID><ISSNLinking>1949-2553</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2008 Sep 1;181(5):3449-55</RefSource><PMID Version="1">18714017</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 1996 Dec 1;184(6):2261-9</RefSource><PMID Version="1">8976181</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncotarget. 2015 May 10;6(13):11310-26</RefSource><PMID Version="1">25888637</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2015 Apr 1;194(7):3201-12</RefSource><PMID Version="1">25740942</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncoimmunology. 2013 Oct 1;2(10):e26527</RefSource><PMID Version="1">24404423</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14145-50</RefSource><PMID Version="1">14610278</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Exp Ther Oncol. 2009;8(1):53-63</RefSource><PMID Version="1">19827271</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Oct 16;371(16):1507-17</RefSource><PMID Version="1">25317870</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Cell Biol. 2013 Nov-Dec;91(10):615-24</RefSource><PMID Version="1">24100387</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Rev. 2014 Jan;257(1):237-49</RefSource><PMID Version="1">24329801</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14943-8</RefSource><PMID Version="1">10611317</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2002 Aug 15;100(4):1265-73</RefSource><PMID Version="1">12149207</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2004 Aug 1;173(3):2143-50</RefSource><PMID Version="1">15265951</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Gene Ther. 1999 May 20;10(8):1359-73</RefSource><PMID Version="1">10365666</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2014 Jan;22(1):18-27</RefSource><PMID Version="1">24048441</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2010 Dec 1;70(23):9591-8</RefSource><PMID Version="1">21098715</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2014 Apr;28(4):917-27</RefSource><PMID Version="1">24067492</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncol Rep. 2015 Jan;33(1):95-102</RefSource><PMID Version="1">25333815</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2005 Nov 1;106(9):2995-3003</RefSource><PMID Version="1">16030195</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bone Marrow Transplant. 1997 Jan;19(2):149-56</RefSource><PMID Version="1">9116612</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2010 Apr;18(4):843-51</RefSource><PMID Version="1">20179677</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 1999 Sep 15;94(6):1855-63</RefSource><PMID Version="1">10477714</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Immunol Immunother. 1993 Oct;37(5):286-92</RefSource><PMID Version="1">8402732</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Apr 18;368(16):1509-18</RefSource><PMID Version="1">23527958</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2005 Feb 15;174(4):2336-42</RefSource><PMID Version="1">15699170</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Aug 25;365(8):725-33</RefSource><PMID Version="1">21830940</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Immunol Immunother. 2015 May;64(5):621-34</RefSource><PMID Version="1">25711293</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2001 Oct;1(1):41-9</RefSource><PMID Version="1">11905813</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2005 Mar 1;174(5):2591-601</RefSource><PMID Version="1">15728465</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Oct 27;10(10):e0140543</RefSource><PMID Version="1">26505904</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2006 May 1;24(13):e20-2</RefSource><PMID Version="1">16648493</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2015 Feb 7;385(9967):517-28</RefSource><PMID Version="1">25319501</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2001 Sep 13;413(6852):165-71</RefSource><PMID Version="1">11557981</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 1998 Jan 15;91(2):419-30</RefSource><PMID Version="1">9427694</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Sci. 2003 Oct;94(10):924-8</RefSource><PMID Version="1">14556668</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Gene Ther. 2013 Oct;24(10):824-39</RefSource><PMID Version="1">23978226</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Biol Cell. 2004 Mar;15(3):1089-100</RefSource><PMID Version="1">14668480</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15</RefSource><PMID Version="1">17062687</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Immunol. 2015 Oct;67(2 Pt A):46-57</RefSource><PMID Version="1">25595028</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Gene Ther. 2013 Mar;24(3):259-69</RefSource><PMID Version="1">23350854</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2013 Oct 15;19(20):5636-46</RefSource><PMID Version="1">23873688</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6</RefSource><PMID Version="1">15980149</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2007 Dec 1;67(23):11428-37</RefSource><PMID Version="1">18056471</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1986 Feb 20-26;319(6055):675-8</RefSource><PMID Version="1">3951539</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2000 Dec 1;165(11):6047-55</RefSource><PMID Version="1">11086036</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 1998 May 15;91(10):3850-61</RefSource><PMID Version="1">9573023</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncotarget. 2016 Apr 26;7(17):23282-99</RefSource><PMID Version="1">26943036</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2005 Jun 15;105(12):4583-9</RefSource><PMID Version="1">15746083</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Front Immunol. 2013 Jun 05;4:135</RefSource><PMID Version="1">23761793</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2003 Dec 1;171(11):5787-94</RefSource><PMID Version="1">14634087</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Mol Med. 2012 Jul;18(7):377-84</RefSource><PMID Version="1">22613370</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncotarget. 2015 Oct 20;6(32):33961-71</RefSource><PMID Version="1">26376680</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2013 Nov 11;24(5):589-602</RefSource><PMID Version="1">24209604</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Ther. 2015 Feb;23(2):330-8</RefSource><PMID Version="1">25373520</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Sep 03;10(9):e0136817</RefSource><PMID Version="1">26334628</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2004 Mar;89(3):338-47</RefSource><PMID Version="1">15020274</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Rev. 2014 Jan;257(1):91-106</RefSource><PMID Version="1">24329792</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gene Ther. 2013 Nov;20(11):1029-32</RefSource><PMID Version="1">23804078</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NK cells</Keyword><Keyword MajorTopicYN="N">T cells</Keyword><Keyword MajorTopicYN="N">chimeric antigen receptor</Keyword><Keyword MajorTopicYN="N">macrophages</Keyword><Keyword MajorTopicYN="N">transgenic mouse</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>04</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27153556</ArticleId><ArticleId IdType="pii">9149</ArticleId><ArticleId IdType="doi">10.18632/oncotarget.9149</ArticleId><ArticleId IdType="pmc">PMC5085178</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D22 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001D22 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27153556
|texte= A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27153556" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |